Most Read Articles
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Roshini Claire Anthony, 26 Feb 2021

Critical or severe COVID-19 disease could raise the risk of negative perinatal outcomes in pregnant women, according to an observational study from the US.

Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.

Dupilumab tied to low serious infection risk, increase in conjunctivitis in AD patients

07 Feb 2021

Treatment with dupilumab confers a low risk of serious infections in patients with atopic dermatitis (AD) but is associated with a clinically meaningful increase in conjunctivitis that requires management in practice, suggest the results of a recent study.

This propensity score-matched cohort study assessed the 6-month risk of conjunctivitis and serious infections in AD patients. The authors used US claims data to compare the risk of such outcomes in individuals receiving either dupilumab, methotrexate (MTX), cyclosporine, or mycophenolate. They also computed relative risks (RRs) after 1:1 propensity score matching.

Of the participants, 1,775 initiated dupilumab, 1,034 MTX, 186 cyclosporine, and 257 mycophenolate. The 6-month risk for any conjunctivitis was highest for users of dupilumab (6.5 percent), followed by initiators of cyclosporine (4.8 percent), MTX (3.3 percent), and mycophenolate (1.2 percent).

After propensity score matching, the RR of any conjunctivitis was heightened in users of dupilumab compared to MTX (RR, 2.45, 95 percent confidence interval [CI], 1.47–4.08), cyclosporine (RR, 1.56, 95 percent CI, 0.69–3.50), and mycophenolate (RR, 7.00, 95 percent CI, 2.12–23.2).

For serious infections, the risk was 0.6 percent for dupilumab and 1.0 percent for MTX (RR, 0.90, 95 percent CI, 0.37–2.20).

The study was limited by analyses based only on few events and by its differential surveillance, according to the authors.

“Dupilumab is an effective treatment for moderate to severe AD with limited safety data in clinical practice,” they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Roshini Claire Anthony, 26 Feb 2021

Critical or severe COVID-19 disease could raise the risk of negative perinatal outcomes in pregnant women, according to an observational study from the US.

Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.